Canada markets close in 54 minutes

Biostage, Inc. (BSTG)

Other OTC - Other OTC Delayed Price. Currency in USD
Add to watchlist
1.2200+0.0600 (+5.17%)
At close: 3:52PM EST
Sign in to post a message.
  • H
    Henry
    Maintaining Sell:

    Biostage (BSTG) closed down -$0.06 to $1.10 with 3,202 shares traded after Friday’s -$0.04 to $1.16 with 700 shares traded, Thursday’s -$0.01 to $1.20 with 2,600 shares trade, Wednesday’s -$0.06 to $1.21 with 400 shares traded and last Tuesday’s -$0.10 to $1.15 with 11,900 shares traded. Reiterating the questions …

    Question#1: Could RSM US LLP suffer of “serious and serial failures” in their audit of BSTG?
    Questio#2: Is there, pressure on the partner to meet internal client retention expectations versus their DUTY to CHECK the RELIABILITY of the liabilities and accounts payables to achieve a rectification of PAST and NOT CARRIED FORWARD accrued and current liabilities?
    Question#3: Shunfu Hu, VP of business development and operations” might” you have conveniently “lost, misplaced or discarded” past and pertinent billings that should have come to the attention of the auditors?
  • H
    Henry
    Maintaining Sell:

    Biostage (BSTG) closed down -$0.02 to $1.16 with 295 shares traded after Wednesday’s -$0.00 to $1.18 with 411 shares traded after Tuesday’s $1.18 with 3,500 shares traded and Monday’s $1.16 with 3,202 shares traded. Reiterating the WHY questions …

    Question#1: WHY does as the share price need to be "propped or pumped" and WHICH “investors” are “stimulating” the volume?
    Question#2: Does it have anything to do with a 52-week low of $0.80 as well as a high of $4.88, a current share price of $1.16 following the last price placement priced at $4.00?
    Question#3: WHY the extension, “BSTG issued warrants to acquire shares of common stock with an exercise price of $3.70 per share that were exercisable until December 31, 2020. On 12/30/20, BSTG agreed to ... extend the expiration date .... to June 30, 2021 with respect to warrants exercisable for an aggregate of 122,554 shares of common stock - their only form of raising capital.
    Question#4: Don’t U.S. public shareholders deserve accountability!
    Question#5: A precarious capital formation platform - they’re running-out of warrant conversions?
    Question#6: Reiterating, WHAT is “with” the $75 million raised and all but spent on getting to an IND with … NO clinical trial initiation?
  • H
    Henry
    Maintaining Sell:

    Biostage (BSTG) closed up +$0.09 to $1.45 with 7,282 shares traded after Friday’s -$0.12 to $1.36 with 110 shares traded after Thursday’s +$0.08 to $1.48 with 3,593 shares traded, Wednesday’s -$0.0285 to $1.39 with 786 shares traded, Tuesday’s +$0.06 to $1.42 with 3,122 shares traded and last Monday’s +$0.01 to $1.36 with 545 shares traded.

    Question#1: WHAT is the “game plan” for the nine (9)-month-old IND to start clinical trials?
    Question#2: is there an exit or endpoint to this scenario as the share price pops and dives to justify or prop the last $4.00 private placement?
    Question#3: Could there also be a … VISA involvement issue here - the United States EB-5 Immigrant Investor Visa Program offers foreign nationals and their unmarried children under 21 the ability to receive permanent residency to the USA. The minimum investment amount for EB-5 is $900,000 USD in a USCIS approved regional center’s project. Could this be another reason behind BSTG’s investment?
  • H
    Henry
    Maintaining Sell:

    Biostage (BSTG) closed up +$ -$0.06 to $1.10 with 3,202 shares traded after Friday’s -$0.04 to $1.16 with 700 shares traded, Thursday’s -$0.01 to $1.20 with 2,600 shares trade, Wednesday’s -$0.06 to $1.21 with 400 shares traded and last Tuesday’s -$0.10 to $1.15 with 11,900 shares traded. Reiterating the questions …

    Question#1: WHY does Chinese investor DST Capital and Beijing based Dixintong Technology Group need a regenerative medicine/biotech public, PPP debtor and money losing company in its investment group that resides in the middle of medical and scientific innovation in America?
    Question#2: Don’t U.S. public shareholders deserve accountability of WHAT is the mission going forward and WHAT data are they accumulating?
  • H
    Henry
    Maintaining Sell:

    Biostage (BSTG) closed up +$0.06 to $1.21 with 366 shares traded after Tuesday’s -$0.10 to $1.15 with 11,943 shares traded, Monday’s flat at $1.25 with 2,652 shares traded and last Thursday’s +$0.04 to $1.15 with 5,491 shares traded. Reiterating the questions …

    Question#1: WHY has eleven (11) months gone by without the initiation of the approved IND clinical trial or even a partnering?
    Question#2: WHAT is Shunfu Hu, VP of business development and operations doing through these months with NO activity to advance the company forward, asleep at the helm?
    Question#3; HOW will RSM US LLP, their accounting firm explain their operational audit of the years progress and the “going concern” issues, lack of audit committee BOD members and the continued rental CFO status?
    Question#4: WHAT is the relationship with Dixintong Technology Group in China and DST Capital from Weston, Mass in funding the company?
  • H
    Henry
    Maintaining Sell:

    Biostage (BSTG) closed down -$0.10 to $1.15 with 11,943 shares traded after Monday’s flat at $1.25 with 2,652 shares traded, Thursday’s +$0.04 to $1.15 with 5,491 shares traded and last Wednesday’s -$0.01 to $1.21 with 6,82 shares traded. Reiterating the questions …

    Question#1: “As previously disclosed (12/30/2020), Biostage issued warrants to acquire shares of common stock with an exercise price of $3.70 per share that were exercisable until December 31, 2020. On December 30, 2020, the Company agreed to extend the expiration date to June 30, 2021 with respect to warrants exercisable for an aggregate of 122,554 shares of common stock.” WHY the extension, can’t they “move” the warrants?
    Question#2: Does it have anything to do with the 2020’s share price depreciation with a 52-week low of $0.80 and a 52-week high of $4.88, a current share price of $1.25 (up from $1.21 on 12/30 and 12/28) following the last price placement priced at $4.00?
    Question#3: HOW will RSM US LLP, their accounting firm explain their operational audit of the years progress and the “going concern” issues, lack of audit committee BOD members and the continued rental CFO status?
    Question#4: is WeChat issue on-coming BAN, a further problem in communication with Chinese dominating investors?
  • H
    Henry
    Maintaining Sell:Biostage (BSTG) closed down -$0.04 to $1.16 with 700 shares traded after Thursday?s -$0.01 to $1.20 with 2,600 shares trade, Wednesday?s -$0.06 to $1.21 with 400 shares traded after Tuesday?s -$0.10 to $1.15 with 11,900 shares traded and last Monday?s flat at $1.25 with 2,652 shares traded. Reiterating the questions ?Question#1: WHO is running this company, WHAT is the relationship with ? LIU #$%$hai of Dixintong Technology Group in China of which Jason Chen, chairman of BSTG and a VP Dixintong. WHAT is LIU #$%$hai?s relationship with DST Capital in funding the company managed and Mrs. bin Zhao?Questio#2: HOW many times did Shunfu Hu, VP of business development and operations say to me ? that Beijing, China based LIU #$%$hai was the ULTIMATE AUTHORITY in BSTG?s future and constantly emphasized and quoted BANKRUPCY as a solution?
  • H
    Henry
    FUNNY that the largest cell phone company in CHINA is behind Biostage (BSTG) and WHY has the company NOT been able to initiate clinical trials after ten (10) months of a FDA initiation approval.QUESTION#1: How is Mrs. bin Zhao of DST Capital, the funder of Biostage (BSTG) related to the chairman and founder of Dixintong Technology Group, whose parent company, D. Phone, is one of the largest smartphone retailers in China and its chairman, LIU #$%$hai; along with BSTG?s chairman, Jason Chen, a V.P. of Dixintong Technology Group?Question#2; WHAT of coincidences, WHO is connecting the dots and WHY the HOLD on trials?
  • H
    Henry
    Maintaining Sell:

    Biostage (BSTG) closed up +$0.04 to $1.15 with 5,491 shares traded after Wednesday’s -$0.01 to $1.21 with 6,82 shares traded, Tuesday’s +$0.01 to $1.22 with 552 shares traded and last Monday’s -$0.20 to $1.21 with 1,700 shares traded. Continuing the questions …

    Question#1: “As previously disclosed (12/30/2020), Biostage issued warrants to acquire shares of common stock with an exercise price of $3.70 per share that were exercisable until December 31, 2020. On December 30, 2020, the Company agreed to extend the expiration date to June 30, 2021 with respect to warrants exercisable for an aggregate of 122,554 shares of common stock.” WHY the extension, can’t they “move” the warrants?
    Question#2: Does it have anything to do with the 2020’s share price depreciation with a 52-week low of $0.80 and a 52-week high of $4.88, a current share price of $1.25 (up from $1.21 on 12/30 and 12/28) following the last price placement priced at $4.00?
    Question#3: A precarious capital formation platform - they’re running-out of warrant conversions?
    Question#4: Reiterating, WHAT is “with” the $75 million raised and all but spent on getting to an IND with … NO clinical trial initiation?
  • H
    Henry
    Maintaining Sell:

    Biostage (BSTG) closed flat at $1.25 with 2,652 shares traded after Thursday’s +$0.04 to $1.15 with 5,491 shares traded, Wednesday’s -$0.01 to $1.21 with 6,82 shares traded and last Tuesday’s +$0.01 to $1.22 with 552 shares traded. Continuing the questions …

    Question#1: “As previously disclosed (12/30/2020), Biostage issued warrants to acquire shares of common stock with an exercise price of $3.70 per share that were exercisable until December 31, 2020. On December 30, 2020, the Company agreed to extend the expiration date to June 30, 2021 with respect to warrants exercisable for an aggregate of 122,554 shares of common stock.” WHY the extension, can’t they “move” the warrants?
    Question#2: Does it have anything to do with the 2020’s share price depreciation with a 52-week low of $0.80 and a 52-week high of $4.88, a current share price of $1.25 (up from $1.21 on 12/30 and 12/28) following the last price placement priced at $4.00?
    Question#3: HOW will RSM US LLP, their accounting firm explain their operational audit of the years progress and the “going concern” issues, lack of audit committee BOD members and the continued rental CFO status?
  • H
    Henry
    Maintaining Sell:

    Biostage (BSTG) closed up +$0.01 to $1.22 with 552 shares traded after Monday’s -$0.20 to $1.21 with 1,700 shares traded after Thursday’s $1.25 with 17,600 shares traded after Wednesday’s +$0.20 to $1.45 with 200 shares traded after last Tuesday’s -$0.20 to $1.25 with 1,400 shares traded. Continuing the questions …

    Question#1: WHAT’s with the $75 million raised and all but spent on getting to an IND and NO clinical trial initiation;
    Question#2: WHAT is the reasoning Mr. William Fodor, chief scientific officer – you “promised” to advance and protect the technology?
    Question#3: The timing and promise of this technology has been “ruined” by your part in NOT delivering a clinical trial initiation to INVESTORS, by NOT speaking up or out against the Chinese board of directors and management; even though you were part of the conceiving group of executives and consultants in the then “new” strategic plan named “forward motion” which you deserted?
  • H
    Henry
    Maintaining Sell:

    Biostage (BSTG) closed down -$0.20 to $1.25 with 16,622 shares traded after Wednesday’s +$0.20 to $1.45 with 159 shares traded, Tuesday’s -$0.20 to $1.25 with 1,398 shares traded and last Monday’s +$0.09 to $1.45 with 7,282 shares traded. Continuing the questions …

    Question#1: WHAT is the “game plan” for the nine (9)-month-old IND to start clinical trials?
    Question#2: DOES RMS US, their accounting “affirm” the status of this company as a “going concern”. A rent-a-CFO and NO AUDIT board members MUST make them question the status – WHY NOT?
    Question#3: WILL RMS US define their OPINION of the on-going “gap” between an IND approval and a clinical trial initiation a publicly-traded company in their year-end review?
  • H
    Henry
    Maintaining Sell:Biostage (BSTG) closed down -$0.01 to $ +$0.06 to $1.21 with 366 shares traded after Tuesday?s -$0.10 to $1.15 with 11,943 shares traded, Monday?s flat at $1.25 with 2,652 shares traded and last Thursday?s +$0.04 to $1.15 with 5,491 shares traded. Reiterating the questions ?Question#1: WHO is running this ?zombie? company, is it really Hong Yu (president) and Shunfu Hu (VP of business development and operations)?Question#2: WHAT is the relationship with ? LIU #$%$hai of Dixintong Technology Group in China of which Jason Chen is a VP and also chairman of BSTG and DST Capital from Weston, Mass in funding the company especially with Mrs. bin Zhao?Questio#3: HOW many times did Shunfu say to me ? directly 20 or 30 times ? that Beijing, China based LIU #$%$hai was the ULTIMATE AUTHORITY in BSTG?s future?
  • H
    Henry
    Maintaining Sell:Biostage (BSTG) closed down -$0.12 to $1.36 with 110 shares traded after Thursday?s +$0.08 to $1.48 with 3,593 shares traded, Wednesday?s -$0.0285 to $1.39 with 786 shares traded, Tuesday?s +$0.06 to $1.42 with 3,122 shares traded and last Monday?s +$0.01 to $1.36 with 545 shares traded.Question#1: WHAT is DST Capital?s connection with Dixintong Technology Group, whose parent company, D. Phone, is one of the largest smartphone retailers in China and its chairman, LIU #$%$hai?Question#2: WHAT is the relationship between Mrs. bin Zhao of DST Capital, the capital funder of Biostage and chairman, LIU #$%$hai of Dixintong Technology Group?Question#3: WHY does Dixintong Technology Group need a regenerative medicine/biotech public, debtor and money loosing company in its investment group that resides in the middle of scientific innovation in America? ? isn?t that CONTRARY to Chinese law?Question#4: Is there another reason to funnel foreign national monies to this entity that has yet to initiate a clinical trial?
  • H
    Henry
    Maintaining Sell:Biostage (BSTG) closed up +$0.08 to $1.48 with 3,593 shares traded after Wednesday?s -$0.0285 to $1.39with 786 shares traded, Tuesday?s +$0.06 to $1.42 with 3,122 shares traded, Monday?s +$0.01 to $1.36 with 545 shares traded and last Friday?s flat at $1.35 with 83 shares traded.Question#1: WHAT is DST Capital?s connection and relationships with Dixintong Technology Group, whose parent company, D. Phone, is one of the largest smartphone retailers in China and its chairman, LIU #$%$hai?Question#2? WHY in many meetings with Shunfu Hu, director of business development and operations did he ? so fear LIU #$%$hai?s control and shut-down of Biostage?
  • H
    Henry
    Maintaining Sell:

    Biostage (BSTG) closed flat again at $1.35 with 83 shares traded after Thursday’s 337 shares traded, Wednesday’s flat with 384 shares traded, Tuesday’s at $1.35 with 761 shares traded and last Monday’s -$0.07 to $1.35 with 5,098 shares traded.

    Question#1: NEVER forget, lawyers for the estate of a deceased individual filed a civil suit in Suffolk Superior Court in Boston, Mass. DO these MULTIPLE issues listed over months contribute to the repricing of share value going forward?
    Question#2: Biostage has to INDEMNIFY Harvard BIO (HBIO) as a result of this litigation; but at what costs going forward in this product liability legal proceeding?
  • H
    Henry
    Maintaining Sell:Biostage (BSTG) closed down -$0.0285 to $1.39with 786 shares traded after Tuesday?s +$0.06 to $1.42 with 3,122 shares traded, Monday?s +$0.01 to $1.36 with 545 shares traded, Friday?s flat again at $1.35 with 83 shares traded and last Thursday?s 337 shares traded.Question#1: WHAT is BSTG?s connection and relationships with Dixintong Technology Group, whose parent company, D. Phone, is one of the largest smartphone retailers in China and its chairman, LIU #$%$hai?
  • H
    Henry
    Maintaining Sell:

    Biostage (BSTG) closed down again -$0.0o to $1.35 with 2,418 shares traded after Wednesday’s -$0.01 to $1.36 with 8,574 shares traded, Tuesday’s +$0.01 to $1.36 with 902 shares traded, Monday’s -$0.01 to $1.35 with 1,575 shares traded and last Friday’s -0.04 to $1.36 with 1,200 shares traded;

    Question#1: WHO or WHICH firm is BUYING (pumping) the shares; it doesn’t seem to be working in protecting the $1.35 share pricing versus the last private placement of $4.00 by Chinese investors?
    Question#2: WILL BSTG fall under the soon to be new “Holding Foreign Companies Accountable Act” WHICH could address longstanding issues around disclosures, transparency and accountability, including limitations on foreign oversight of majority owned Chinese companies?
    Question#3; The Boston Business Journal (yesterday) questioned life science firms that received PPP loans even though they had previously or afterwards received private placement monies ($1 million by BSTG). COULD these circumstances “serve as more than a warning … that the FBI and law enforcement partners will aggressively go after bad actors who are utilizing the COVID-19 pandemic as an opportunity to commit fraud”, said Joseph Bonavolonta, special agent in charge of the FBI’s Boston field office.
  • H
    Henry
    Maintaining Sell:

    Biostage (BSTG) closed flat again at $1.35 with 337 shares traded with after Wednesday’s flat with 384 shares traded, Tuesday’s at $1.35 with 761 shares traded, Monday’s -$0.07 to $1.35 with 5,098 shares traded and last Friday’s +$0.07 to $1.42 with 3,514 shares traded.

    Question#1: WHO is working in the 17,00 square feet facility at 84 October Hill Road, Holliston, Ma and related costs and expenses of operating without employees?
    Question#2: HOW long can their sources of liquidity hang-on with an accumulated deficient of approximately $75 + million dollars without any trial and results?
    Question#3: WHO and WHAT determines the waste of the past and the issues of going forward?
  • H
    Henry
    Maintaining Sell:

    Biostage (BSTG) closed up +$0.045 with 1,010 shares traded to $1.47 after Thursday’s -$0.075 with 800 shares traded, Wednesday’s flat at $1.50 with 55 shares traded after Tuesday’s +$0.15 to $1.50 with 200 shares traded and last Monday’s -$0.25 to $1.35 with 2.235 shares traded).

    Question#1: BSTG stated in its Q3 earnings’ 8-K, “Following the approval of Biostage’s Investigational New Drug Application from U.S. Food and Drug Administration (FDA) in March of this year, Biostage continued its efforts during the third quarter for clinical planning, including engaging with clinical research organizations as well as other contract research organizations in advance of the start of the clinical trial for the Company’s CEI product candidate.” With ONLY $2 million in cash and a PPP debt of $421 K; HOW are they going to AFFORD a trial?
    Question#2: WHY can’t BSTG jump into the pediatric market; they MUST COMPLETE 3-5 adult patient trial before they can even file for a NEW pediatric IND; isn’t that fact TRUE?